post-cal color out-performance
addit color echo peer highlight similar underli trend
bolster quarter outlook year strength specialti
growth largest custom strength health system partner
increas gener penetr within variou custom also help quarter
manag indic benefit intern quarter better
expect healthcar benefit tune coupl cent
expect repeat also achiev synergi target earlier expect
hd smith acquisit price brand inflat remain mid-singl
digit rang gener deflat gener in-lin origin expect
area necessarili better despit industri data show may
better despit big gener launch occur earlier year manag
indic specif benefit quarter discern
trend pharmedium less headwind quarter less loss y/i
audit process current way may complet month recal
indic pharmedium unlik return histor volum level next
coupl year audit posit step busi segment
strong perform mwi vet stem improv companion market
growth nation account canadian consult busi
rais estim pt given solid result rais ep estim
rais improv backdrop
pharma distribut segment addit expect
compani see lower interest expens better trend gener price
improv growth prospect rais pt base new
higher price-to-earnings ep
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight gain
share via largest custom walgreen
compani continu face headwind relat
pharmedium busi overhang relat
upsid case see modest multipl expans
gener price deflat come better fear
greater growth specialti market
downsid case see continu persist
gener deflat continu problem
pharmedium bring compani peer
growthmid singl digit mid singl digit mid singl digit mid singl digit oper expens growthmid singl digit growthtrack high end mid singl digit growthtrack high end mid singl digit growthtrack high end mid singl digit growthdistribut servic op profit growth mid singl digit growth singl digit growth singl digit op profit growthhigh singl digit growthhigh singl digit growthhigh singl digit growthhigh singl digit growthoper profit growth mid singl digit singl digit growth singl digit interest y/yer origin anticipated origin anticipatedadj effect tax changebrand inflationmid-singl digit inflationmid-singl digit inflationmid-singl digit inflationmid-singl digit inflationgener deflationsimilar tail end tail end tail end tail end stabl nowbeliev stabl nowbeliev stabl nowbeliev stabl nowshar ep ep flat barclay corp
amerisourcebergen revenu profit model
 annual revenu model mil abcabcabcabcabcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcabcabcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcabcabcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom ebit barclay corp
 quarterli incom statement mil ep ep ep ep ep ep distribut sell oper addback check excl intang asset ens rate interest ens check ep fulli dilut share growth distribut sell per barclay corp
 annual revenu model mil abcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmtotal ebit barclay corp
 annual incom statement distribut sell oper addback check excl intang asset ens rate interest ens check ep fulli dilut share growth distribut sell per barclay corp
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
